ASH Annual Meeting | Conferences

Higher CPX-351 Induction Doses Lead to Delayed Hematologic Recovery in AML

December 08, 2020

Treatment with higher doses of CPX-351 in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia was significantly associated with prolonged hematologic recovery times during induction cycles 1 and 2.

Results of Selinexor Added to Pd Regimen Moves Myeloma Study on to Phase 3

December 08, 2020

The combination of selinexor plus pomalidomide and low-dose dexamethasone led to favorable responses in a cohort of patients with heavily pretreated multiple myeloma, warranting further investigation of the regimen in a phase 3 trial.

Brentuximab Vedotin Tolerable With High Response Rates in Older Patients with cHL

December 08, 2020

In older patients with comorbid classical Hodgkin lymphoma who are deemed unfit for combination chemotherapy, treatment with the antibody dug conjugate brentuximab vedotin appeared tolerable and achieved high response rates that were durable in some patients, according to results from the phase 2 SGN35-015 study.

Acalabrutinib Demonstrates Low Cardiac Risk in Chronic Lymphocytic Leukemia

December 08, 2020

In a pooled analysis of 4 clinical trials in chronic lymphocytic leukemia, patients who received treated with acalabrutinib monotherapy had a low incidence of cardiac toxicities leading to treatment discontinuation, according to a presentation given during the American Society of Hematology Annual Meeting.

Significant Responses Seen With Investigational BTK Inhibitor in Pretreated CLL/SLL Population

December 08, 2020

A high objective response rate was observed in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with LOXO-305, according to results of the phase 1/2 BRUIN trial presented during the 2020 ASH Annual Meeting.

Mosunetuzumab Elicits High and Durable Responses in Subgroups of Patients With FL

December 08, 2020

A phase clinical trial has demonstrated that administering a mosunetuzumab fixed-duration leads to high, durable, and consistent responses in patients with follicular lymphoma across multiple subgroups. Data from the study were presented during the virtual 2020 American Society of Hematology Annual Meeting.